FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891141671> ?p ?o ?g. }

• W2891141671 endingPage "7502" @default.
• W2891141671 startingPage "7502" @default.
• W2891141671 abstract "7502 Background: Ibr, a first-in-class, once-daily BTK inhibitor, is approved in the US and EU for CLL treatment, including del17p. Early studies support synergistic antitumor activity with combined ibr and ven, a BCL-2 inhibitor approved by FDA for relapsed del17p CLL. Single-agent ibr lead-in may lower tumor lysis syndrome (TLS) risk by debulking prior to adding ven. PCYC-1142 (CAPTIVATE) is a multicenter, phase 2 study of ibr + ven (I+V) in first-line CLL (NCT02910583) evaluating if remission with undetectable minimal residual disease (MRD(-)) after I+V can provide pts treatment holidays. Methods: Treatment-naïve pts <70 y with active CLL/SLL by IWCLL criteria receive single-agent ibr (420 mg/d PO) lead-in (3 x 28 d cycles) before initiating ven ramp-up to 400 mg/d PO. MRD (<0.01% by flow) is assessed in peripheral blood (PB) after 6 cycles I+V. MRD and response in bone marrow (BM) are assessed after 12 cycles I+V with planned randomization and intervention based on MRD status. Results: 163 pts were enrolled (median 58 y; 14% del17p; 15% del11q; 33% longest lymph node diameter [LDi] ≥5 cm). The first 14 pts enrolled for safety run-in completed ≥6 cycles I+V (median treatment duration, 9.9 mo ibr, 7.2 mo ven). No dose-limiting toxicities occurred during safety run-in; response was seen in 14/14 (CR confirmed in 1/5 early BM; 13/14 PR); PB was MRD(-) in 9/11 assessed pts. 97 pts (including 14 safety run-in pts) completed ibr lead-in plus ≥1 dose of ven (I+V Exposed). AEs in ≥20% of I+V Exposed pts were diarrhea (39%), fatigue (23%), nausea (23%) and arthralgia (21%); grade ≥3 AEs in ≥3% were neutropenia (10%), hypertension (3%) and thrombocytopenia (3%). No clinical TLS occurred; lab TLS was seen in 1/163 pts. In I+V Exposed pts with baseline LDi ≥5 cm, LDi decreased to <5 cm in 19/30 pts (63%) after ibr lead-in. TLS risk shifted from high to medium/low in 17/22 pts (77%); overall, proportion of high-risk TLS decreased from 23% at baseline to 3% after ibr lead-in. Conclusions: Early data show promising activity of I+V oral regimen with MRD(-) response in 82% in first-line CLL. Safety was consistent with AE profiles of single-agent ibr or ven. The protocol-specified efficacy analysis in the first 30 pts will be presented. Clinical trial information: NCT02910583." @default.
• W2891141671 created "2018-09-27" @default.
• W2891141671 creator A5000959540 @default.
• W2891141671 creator A5002467749 @default.
• W2891141671 creator A5005565037 @default.
• W2891141671 creator A5008054206 @default.
• W2891141671 creator A5026842309 @default.
• W2891141671 creator A5027725333 @default.
• W2891141671 creator A5034517642 @default.
• W2891141671 creator A5035549893 @default.
• W2891141671 creator A5036828560 @default.
• W2891141671 creator A5040412322 @default.
• W2891141671 creator A5053787554 @default.
• W2891141671 creator A5054841750 @default.
• W2891141671 creator A5081161234 @default.
• W2891141671 creator A5085393928 @default.
• W2891141671 creator A5087770514 @default.
• W2891141671 creator A5089428686 @default.
• W2891141671 creator A5089625305 @default.
• W2891141671 date "2018-05-20" @default.
• W2891141671 modified "2023-09-25" @default.
• W2891141671 title "Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL)." @default.
• W2891141671 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7502" @default.
• W2891141671 hasPublicationYear "2018" @default.
• W2891141671 type Work @default.
• W2891141671 sameAs 2891141671 @default.
• W2891141671 citedByCount "21" @default.
• W2891141671 countsByYear W28911416712019 @default.
• W2891141671 countsByYear W28911416712020 @default.
• W2891141671 countsByYear W28911416712021 @default.
• W2891141671 countsByYear W28911416712022 @default.
• W2891141671 crossrefType "journal-article" @default.
• W2891141671 hasAuthorship W2891141671A5000959540 @default.
• W2891141671 hasAuthorship W2891141671A5002467749 @default.
• W2891141671 hasAuthorship W2891141671A5005565037 @default.
• W2891141671 hasAuthorship W2891141671A5008054206 @default.
• W2891141671 hasAuthorship W2891141671A5026842309 @default.
• W2891141671 hasAuthorship W2891141671A5027725333 @default.
• W2891141671 hasAuthorship W2891141671A5034517642 @default.
• W2891141671 hasAuthorship W2891141671A5035549893 @default.
• W2891141671 hasAuthorship W2891141671A5036828560 @default.
• W2891141671 hasAuthorship W2891141671A5040412322 @default.
• W2891141671 hasAuthorship W2891141671A5053787554 @default.
• W2891141671 hasAuthorship W2891141671A5054841750 @default.
• W2891141671 hasAuthorship W2891141671A5081161234 @default.
• W2891141671 hasAuthorship W2891141671A5085393928 @default.
• W2891141671 hasAuthorship W2891141671A5087770514 @default.
• W2891141671 hasAuthorship W2891141671A5089428686 @default.
• W2891141671 hasAuthorship W2891141671A5089625305 @default.
• W2891141671 hasConcept C126322002 @default.
• W2891141671 hasConcept C141071460 @default.
• W2891141671 hasConcept C2776694085 @default.
• W2891141671 hasConcept C2777063308 @default.
• W2891141671 hasConcept C2777938653 @default.
• W2891141671 hasConcept C2778461978 @default.
• W2891141671 hasConcept C2779675984 @default.
• W2891141671 hasConcept C2779788671 @default.
• W2891141671 hasConcept C2779878957 @default.
• W2891141671 hasConcept C29730261 @default.
• W2891141671 hasConcept C38652104 @default.
• W2891141671 hasConcept C41008148 @default.
• W2891141671 hasConcept C71924100 @default.
• W2891141671 hasConcept C90924648 @default.
• W2891141671 hasConcept C9583187 @default.
• W2891141671 hasConceptScore W2891141671C126322002 @default.
• W2891141671 hasConceptScore W2891141671C141071460 @default.
• W2891141671 hasConceptScore W2891141671C2776694085 @default.
• W2891141671 hasConceptScore W2891141671C2777063308 @default.
• W2891141671 hasConceptScore W2891141671C2777938653 @default.
• W2891141671 hasConceptScore W2891141671C2778461978 @default.
• W2891141671 hasConceptScore W2891141671C2779675984 @default.
• W2891141671 hasConceptScore W2891141671C2779788671 @default.
• W2891141671 hasConceptScore W2891141671C2779878957 @default.
• W2891141671 hasConceptScore W2891141671C29730261 @default.
• W2891141671 hasConceptScore W2891141671C38652104 @default.
• W2891141671 hasConceptScore W2891141671C41008148 @default.
• W2891141671 hasConceptScore W2891141671C71924100 @default.
• W2891141671 hasConceptScore W2891141671C90924648 @default.
• W2891141671 hasConceptScore W2891141671C9583187 @default.
• W2891141671 hasIssue "15_suppl" @default.
• W2891141671 hasLocation W28911416711 @default.
• W2891141671 hasOpenAccess W2891141671 @default.
• W2891141671 hasPrimaryLocation W28911416711 @default.
• W2891141671 hasRelatedWork W2470301306 @default.
• W2891141671 hasRelatedWork W2580821712 @default.
• W2891141671 hasRelatedWork W2750813742 @default.
• W2891141671 hasRelatedWork W2891141671 @default.
• W2891141671 hasRelatedWork W2893126727 @default.
• W2891141671 hasRelatedWork W2973729030 @default.
• W2891141671 hasRelatedWork W3014972780 @default.
• W2891141671 hasRelatedWork W3125377580 @default.
• W2891141671 hasRelatedWork W4296529188 @default.
• W2891141671 hasRelatedWork W3083222230 @default.
• W2891141671 hasVolume "36" @default.
• W2891141671 isParatext "false" @default.
• W2891141671 isRetracted "false" @default.
• W2891141671 magId "2891141671" @default.
• W2891141671 workType "article" @default.